April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

• Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • GlaxoSmithKline have discontinued Zofran 2 mL vials. • Hospira has ondansetron on shortage due to quality improvement issues. Ondansetron 32 mg/50 mL premixed bags • Hospira has ondansetron premixed bags on shortage due to changes in the manufacturing process. • Claris recalled all lots of their ondansetron premixed bags in mid-2010. • Pfizer discontinued their ondansetron premixed bags in January, 2012. • Sagent has discontinued their ondansetron premixed bags. • Teva has ondansetron premixed bags on shortage due to manufacturing delays. • West-Ward has discontinued their ondansetron premixed bags. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=510 Source: www.ashp.org Magnesium Sulfate Injection March 28, 2012 Products Affected - Description Magnesium sulfate injection, American Regent 500 mg/mL, 2 mL vial (NDC 00517-2602-25) 500 mg/mL, 10 mL vial (NDC 00517-2610-25) 500 mg/mL, 50 mL vial (NDC 00517-2650-25) Magnesium sulfate injection, APP 500 mg/mL, 2 mL vial (NDC 63323-0064-02) 500 mg/mL, 10 mL vial (NDC 63323-0064-10) 500 mg/mL, 20 mL vial (NDC 63323-0064-20) 500 mg/mL, 50 mL vial (NDC 63323-0064-50) Magnesium sulfate injection, Hospira 500 mg/mL, 10 mL syringe (NDC 00409-1754-10) 500 mg/mL, 20 mL vial (NDC 00409-2168-02) 10 mg/mL, 100 mL premixed bag (NDC 00409-6727-23) 40 mg/mL, 50 mL premixed bag (NDC 00409-6729-24) 40 mg/mL, 100 mL vials premixed bag (NDC 00409-6729-23) 40 mg/mL, 500 mL vials premixed bag (NDC 00409-6729-03) 40 mg/mL, 1000 mL premixed bag (NDC 00409-6729-09) 80 mg/mL, 50 mL premixed bag (NDC 00409-6730-13) Reason for the Shortage • American Regent had temporarily suspended distribution of most drug products including magnesium sulfate injection in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. • APP has magnesium sulfate injection on shortage due to increased demand for the product. • Hospira has magnesium sulfate injection on shortage due to manufacturing delays. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=757 Source: www.ashp.org Lidocaine Injection March 28, 2012 Products Affected - Description 68
Lidocaine 0.5% Xylocaine 0.5% injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0484-57) Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57) Lidocaine 0.5%, Hospira 5 mg/mL, 50 mL SD Tear Top Vial, preservative-free (NDC 00409-4278-01) Lidocaine 1% Lidocaine 1% injection, APP 10 mg/mL, 2 mL vial (NDC 63323-0201-02) 10 mg/mL, 10 mL vial (NDC 63323-0201-10) Xylocaine 1% injection, APP 10 mg/mL, 20 mL vial (NDC 63323-0485-27) 10 mg/mL, 50 mL vial (NDC 63323-0485-57) Xylocaine 1% - MPF injection, APP 10 mg/mL, 2 mL vial (NDC 63323-0492-27) 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80) 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89) 10 mg/mL, 5 mL vial (NDC 63323-0492-57) 10 mg/mL, 30 mL vial (NDC 63323-0492-37) 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31) Lidocaine 1% injection, Hospira 10 mg/mL, 30 mL preservative-free vial (NDC 00409-4279-02) 10 mg/mL, 20 mL vial (NDC 00409-4276-01) 10 mg/mL, 50 mL vial (NDC 00409-4276-02) 10 mg/mL, 2 mL preservative-free glass ampule (NDC 00409-4713-32) 10 mg/mL, 5 mL preservative-free glass ampule (NDC 00409-4713-02) 10 mg/mL, 30 mL preservative-free vial, sterile pack (NDC 00409-4270-01) 10 mg/mL, 5 mL Ansyr plastic emergency syringes (NDC 00409-9137-05) Lidocaine 1.5% Xylocaine 1.5% - MPF injection, APP 15 mg/mL, 10 mL ampule (NDC 63323-0493-97) 15 mg/mL, 20 mL ampule (NDC 63323-0493-91) Lidocaine 1.5% injection, Hospira 15 mg/mL, 20 mL ampule, preservative-free (NDC 00409-4776-01) 15 mg/mL, 20 mL sterile pack, glass ampule, preservative-free (NDC 00409-4056-01) Lidocaine 2% Lidocaine 2% injection, APP 20 mg/mL, 2 mL vial (NDC 63323-0202-02) 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05) Xylocaine 2% injection, APP 20 mg/mL, 10 mL vial (NDC 63323-0486-17) 20 mg/mL, 20 mL vial (NDC 63323-0486-27) 20 mg/mL, 50 mL vial (NDC 63323-0486-57) 20 mg/mL, 10 mL vial (NDC 63323-0486-10) – NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20) – NDC discontinued 20 mg/mL, 50 mL vial (NDC 63323-0486-50) – NDC discontinued 69
Page 1 and 2:
April 2012 Drug Information Update
Page 3 and 4:
First-Time Generics GENERIC DRUG NA
Page 5 and 6:
GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8:
Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10:
Statin Drugs - Drug Safety Communic
Page 11 and 12:
Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14:
low blood sugar (hypoglycemia) in p
Page 15 and 16:
Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67: 2 mL iSecure syringe (NDC 00406-112
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?